Study of Efficacy and Safety of Non-myeloablative Haploidentical Stem Cell transplantation using post-transplant cyclophosphamide for refractory hematological malignancies. - Haplo-HSCT-RIC

Okamura Atsuo0 个研究点目标入组 23 人开始时间: 2019年3月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Hematopoietic malignant tumors suitable for hematopoietic stem cell transplantation
•2. Disease status; remission phase or non-remission phase
•3. Age; >=16 year-old, <=65 year-old
•4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 2
•5. Adequate organ function:
•a. Ejection fraction >=50%
•b. T-Bil <= 2.0 mg/dl, AST and ALT <= 3 times of the high end of the normal range
•c. CCr >=30ml/min
•d. SpO2 >=95% (room air)
•6. No HLA-matched related donor
•7. No HLA-matched unrelated donor
•8. Written informed consent

•1. HIV antibody positivity
•2. Active multiple primary cancers
•3. Active infection
•4. Pregnant, unwilling to practice contraception during the study, or lactating female
•5. Hypersensitivity to agents used for conditioning and GVHD prophylaxis
•6. Specific HLA antibody against donor HLA
•7. Administration of anticancer drugs except the study protocol within 13 days before transplantation
•8. Other, determination of the attending physician

发起方

Okamura Atsuo